HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

AuthorsAlessandro M Vannucchi
JournalThe New England journal of medicine (N Engl J Med) Vol. 372 Issue 17 Pg. 1670-1 (04 23 2015) ISSN: 1533-4406 [Electronic] United States
PMID25901432 (Publication Type: Letter, Comment)
Chemical References
  • Antineoplastic Agents
  • Pyrazoles
  • Janus Kinases
Topics
  • Antineoplastic Agents (therapeutic use)
  • Female
  • Humans
  • Janus Kinases (antagonists & inhibitors)
  • Male
  • Polycythemia Vera (drug therapy)
  • Pyrazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: